Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist

摘要

An improved adjuvant treatment of metastatic breast cancer in which patients are administered an anthracycline chemotherapeutic agent and a taxane chemotherapeutic agent is provided in which a diphenyl compound which is a potent antagonist of histamine binding at the intracellular histamine receptor is initially administered prior to administration of the chemotherapeutic agents.